ClinicalTrials.gg
RecruitingNCT03127267Updated Sep 12, 2025

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

A Phase 3 interventional study of Masitinib (6.0) and Riluzole in Amyotrophic Lateral Sclerosis, sponsored by AB Science. Recruiting at 56 sites in 17 countries. Open to participants aged 18 Years to 81 Years. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by AB Science · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2021; still recruiting 5 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
495
Allocation
Randomized
Ages
18 Years to 81 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 132 studies in Amyotrophic Lateral Sclerosis with a site in France — 28 open to participants now, 36 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · France.

Planned enrollment
11th of 103
495 · median 83
Started
2021
with 13 others
Phase 3
25 of 132
2 open now
Primary completion
2027-12
later than 23 of 35 live
Registered
55th of 132
by date

Among the 132 studies in Amyotrophic Lateral Sclerosis with a site in France, this one is the 11th largest by planned enrollment of the 103 interventional ones that give a count, is one of 14 that started in 2021, is one of 25 in phase 3, reaches primary completion later than 23 of the 35 other live ones, and was the 55th registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

28 of the 132 studies in Amyotrophic Lateral Sclerosis with a site in France are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 81 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies in Amyotrophic Lateral Sclerosis with a site in France, or all of them as a file.
02

Study summary

The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Read the detailed description

Masitinib is a selective, oral tyrosine kinase inhibitor with neuroprotective capability demonstrated via numerous preclinical studies. Two of masitinib's main cellular targets are the mast cell and microglia cell. It is well-established that mast cells play a prominent role in neuroinflammatory processes. Microglia, resident immune cells of the central nervous system (CNS), also constitute an important source of neuroinflammatory mediators and may have fundamental roles in numerous neurodegenerative disorders. The development of masitinib in ALS is therefore based on the pharmacological action of masitinib in microglia cells and mast cells, thereby slowing microglial-related disease progression, reducing neuro-inflammation, and modulating the neuronal microenvironment in both central and peripheral nervous systems. This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group (two ascending dose titrations of masitinib and matching placebo), comparative study of oral masitinib in the treatment of patients with amyotrophic lateral sclerosis (ALS).

03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • Amyotrophic Lateral Sclerosis
  • ALS
  • Tyrosine kinase inhibitor
  • Lou Gehrig's disease
  • Charcot's disease
  • Motor Neuron disease
  • MND
04

Who can participate

Ages eligible
18 Years to 81 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main inclusion criteria include:

  • Patients diagnosed with laboratory supported probable, clinically probable or definite ALS according to the World Federation of Neurology Revised El Escorial criteria
  • Patient with a familial or sporadic ALS
  • ALS disease duration from diagnosis no longer than 24 months at the screening visit
  • Patient treated with a stable dose of riluzole (100 mg/day) for at least 12 weeks days prior to the baseline visit
  • Patient with an ALSFRS-R score progression between onset of the disease and screening of > 0.3 per month, confirmed with an ALSFRS-R score progression of ≥ 1 point during a 12-week run-in period between screening and randomization.
  • Patient with a score, at screening, of at least 26 overall, including a score of at least 3 on item #3 and at least 2 on each of the 12 ALSFRS-R individual component items and with a score, at randomization, of at least 2 on each of the 12 ALSFRS-R individual component items

Main exclusion criteria include:

  • Patient with dementia or significant neurological, psychiatric, systemic or organic disease, uncontrolled or that may interfere with the conduct of the trial or its results
  • Patient with a FVC \< 60% predicted normal value for gender, height, and age at screening and baseline
  • Pregnant, or nursing female patient
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
495 participants (estimated)

Study arms

  • Experimental
    Masitinib (4.5) & Riluzole

    Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control. Masitinib will be administered as an add-on to riluzole at 50 mg b.i.d

    Drug: Riluzole · Drug: Masitinib (4.5)

  • Experimental
    Masitinib (6.0) & Riluzole

    Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control. Masitinib will be administered as an add-on to riluzole at 50 mg b.i.d.

    Drug: Masitinib (6.0) · Drug: Riluzole

  • Placebo comparator
    Placebo & Riluzole

    Participants receive a matched dose placebo, given orally twice daily, in combination with riluzole at 50 mg b.i.d.

    Drug: Riluzole · Drug: Placebo

Interventions

  • Masitinib (titration to 6.0 mg/kg/day)

    Also known as: AB1010

  • Riluzole 50 mg tablet, treatment per os

    Also known as: Rilutek

  • DrugPlacebo

    treatment per os

    Also known as: Placebo Oral Tablet

  • Masitinib (titration to 4.5 mg/kg/day)

    Also known as: AB1010

06

What researchers measure

Primary outcomes

  1. ALSFRS-R

    Change in Amyotrophic Lateral Sclerosis functional rating scale (ALSFRS)-Revised.

    Time frame: 48 weeks

Secondary outcomes

  1. ALSAQ-40

    Change in ALS quality of life patient questionnaire (ALSAQ-40)

    Time frame: 48 weeks

  2. PFS

    Progression free survival (PFS) is defined as the time from randomization to progression (decline of more than 9 points in ALSFRS-R score from baseline) or death

    Time frame: From day of randomization to disease progression or death, assessed for a maximum of 36 months

  3. FVC

    Change in Forced Vital Capacity (FVC)

    Time frame: 48 weeks

  4. HHD

    Change in evaluation of upper- and lower-limb muscle strength using hand-held dynamometry (HHD)

    Time frame: 48 weeks

  5. Change in the Combined Assessment of Function and Survival (CAFS) score from baseline to week 48

    CAFS ranks patients' clinical outcomes based on survival time and change in the ALS Functional Rating Scale-Revised (ALSFRS-R) score. Each patient's outcome is compared to every other patient's outcome, assigned a score, and the summed scores are ranked. The mean rank score for each treatment group can then be calculated. A higher mean CAFS score indicates a better group outcome.

    Time frame: 48 weeks

07

Study locations

55 of 56 sites recruiting
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
    Recruiting
  • University of Southern California
    Los Angeles, California 90007, United States
    Recruiting
  • University of Kentucky
    Lexington, Kentucky 40506, United States
    Recruiting
  • Johns Hopkins Medicine Brain Science Institute
    Baltimore, Maryland 21205, United States
    Recruiting
  • Lahey Hospital and Medical Center
    Burlington, Massachusetts 01805, United States
    Recruiting
  • University of Virginia Health System
    Charlottesville, Virginia 22903, United States
    Recruiting
  • University Hospital Leuven (UZ Leuven)
    Leuven, Belgium
    Recruiting
  • Bispebjerg Hospital
    Copenhagen, Denmark
    Recruiting
  • CHU de Angers
    Angers, France
    Recruiting
  • Groupe Hospitalier Pellegrin Tripode
    Bordeaux, France
    Recruiting
  • Hôpital neurologique Pierre Wertheimer
    Bron, France
    Recruiting
  • CHU Gabriel Montpied
    Clermont-Ferrand, France
    Recruiting
  • CHU de Lille - Hopital Roger Salengro
    Lille, France
    Recruiting
  • CHU de Limoges - Hôpital Dupuytren
    Limoges, France
    Recruiting
  • CHU de Marseille - Hôpital de la Timone
    Marseille, France
    Recruiting
  • CHRU de Montpellier - Gui de Chauliac
    Montpellier, France
    Recruiting
  • CHU de Nancy - Hopital Central
    Nancy, France
    Recruiting
  • CHU Hôpital Pasteur Nice
    Nice, France
    Recruiting
  • CHRU de Tours - Hopital Bretonneau
    Tours, France
    Recruiting
  • Department of Neurology, University of Ulm
    Ulm, 89081, Germany
    Not yet recruiting
  • Athens Naval Hospital
    Athens, Greece
    Recruiting
  • Eginition Hospital
    Athens, Greece
    Recruiting
  • University General Hospital of Larissa
    Larissa, Greece
    Recruiting
  • General University Hospital of Patras
    Rio, Greece
    Recruiting
  • Hadassah University Hospital
    Jerusalem, Israel
    Recruiting
  • Tel-Aviv Medical Center Hôpital Sourasky (ICHILOV)
    Tel Aviv, Israel
    Recruiting
  • Ospedale Civile Sant'Agostino - Estense
    Baggiovara, Modena, Italy
    Recruiting
  • ASST degli Spedali Civili di Brescia
    Brescia, Italy
    Recruiting
  • Centro Clinico NeMO Fondazione Serena Onlus
    Gussago, Italy
    Recruiting
  • Clinico Nemo Center (Centro Clinico NeMO Milano)
    Milan, Italy
    Recruiting
  • IRCCS Istituto Auxologico Italiano
    Milan, Italy
    Recruiting
  • Istituti Clinici Scientifici Maugeri IRCCS
    Milan, Italy
    Recruiting
  • San Raffaele Hospital (Ospedale San Raffaele)
    Milan, Italy
    Recruiting
  • University Hospital Maggiore della Carita
    Novara, Italy
    Recruiting
  • Azienda Ospedale-Università Padova
    Padova, Italy
    Recruiting
  • IRCCS Mondino Foundation
    Pavia, Italy
    Recruiting
  • University Hospital in Turin (Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino)
    Torino, Italy
    Recruiting
  • Oslo University Hospital HF Ullevål
    Oslo, Norway
    Recruiting
  • Centrum Medyczne Neuromed
    Bydgoszcz, Poland
    Recruiting
  • Hospital de Santa Maria
    Lisbon, Portugal
    Recruiting
  • Moscow city clinical Hospital after V.M. Buyanov
    Moscow, Russia
    Recruiting
  • Scientific Practical Medical Center "Innovation and Health"
    Novosibirsk, Russia
    Recruiting
  • Clinical Centre of Serbia
    Belgrade, Serbia
    Recruiting
  • Klinicni center Ljubljana
    Ljubljana, Slovenia
    Recruiting
  • Hospital General Universitario de Alicante
    Alicante, Spain
    Recruiting
  • Hospital Universitari de Bellvitge
    Barcelona, Spain
    Recruiting
  • Hospital Carlos III
    Madrid, Spain
    Recruiting
  • Hospital San Rafael
    Madrid, Spain
    Recruiting
  • Clinical Hospital Santiago de Compostela
    Santiago de Compostela, Spain
    Recruiting
  • Hospital Universitario y Politecnico La Fe
    Valencia, Spain
    Recruiting
  • Centralsjukhuset Karlstad (Central Hospital Karlstad)
    Karlstad, Sweden
    Recruiting
  • Skåne University Hospital
    Malmö, Sweden
    Recruiting
  • Norrlands universitetssjukhus
    Umeå, Sweden
    Recruiting
  • The State Institution of Neurology, Psychiatry and Narcology of NAMS of Ukraine
    Kharkiv, Ukraine
    Recruiting
  • Medical Center of LLC Medical Center Dopomoga Plus
    Kyiv, Ukraine
    Recruiting
  • Communal Non-Profit Enterprise of Lviv Regional Council, Lviv Regional Clinical Hospital, Neurological Department
    Lviv, Ukraine
    Recruiting
08

References and documents

Publications

  • Latham BD, Oskin DS, Crouch RD, Vergne MJ, Jackson KD. Cytochromes P450 2C8 and 3A Catalyze the Metabolic Activation of the Tyrosine Kinase Inhibitor Masitinib. Chem Res Toxicol. 2022 Sep 19;35(9):1467-1481. doi: 10.1021/acs.chemrestox.2c00057. Epub 2022 Sep 1. PubMed 36048877 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Dec 2027, 82 months after the start.

Of 24 phase 3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's planned 82 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2017
First posted
Apr 25, 2017
StartActual
Feb 2, 2021
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03127267
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Apr 25, 2017
Start date
Feb 2, 2021
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 12, 2025

Study contacts

Clinical Study Coordinator
Contact
clinical@ab-science.com
+33(0)147200014
Albert Ludolph, MD, PhD
principal investigator · Department of Neurology, University of Ulm, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion